Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Indivior Plc ADR (OP: INVVY )

25.12 -0.78 (-3.01%)
Streaming Delayed Price Updated: 11:03 AM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 769
Open 24.68
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 25.90
Today's Range 24.68 - 25.12
52wk Range 14.22 - 75.98
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Indivior Targeting Listing On NASDAQ For The Spring Of 2023
Indivior PLC (OTCPK:INVVY) (LON:INDV) will hold a capital markets day on December 7th in New York City. The event will be hosted by Mark Crossley, CEO, along with members of the Indivior executive... 
Via Benzinga
Facebook Stalls Portal & Smartwatch Projects, Visa Breaks Debit Card Tie Up With FTX, $3B Bitcoin Withdrawn From Crypto Exchanges: Top Stories Monday, Nov. 14
Reuters 
Via Benzinga

Performance

YTD
+11.06%
+11.06%
1 Month
+14.18%
+14.18%
3 Month
+30.83%
+30.83%
6 Month
+29.75%
+29.75%
1 Year
+62.58%
+62.58%

More News

Read More
Indivior To Pay Over 100% Premium To Buy Opioid Focused Player Opiant Pharmaceuticals
Via Benzinga
Hypocrisy All Around: Pfizer, NFL Are Hidden Sponsors Of Anti-Drug Group Fighting Against Cannabis Legalization
Via Benzinga
Indivior Positioned To Profit If Aelis Farma's Study Of Cannabis Use Disorder Succeeds
Via Benzinga
Indivior Study Shows Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression In Chronic Opioid Users
Via Benzinga
Cannabis Movers & Shakers: MedMen, IM Cannabis, Avicanna, Avant Brands
Via Benzinga
Using Opioid Addiction Drug Buprenorphine May Cause Dental Issues, FDA Flags
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.